Lytenava (bevacizumab-vikg)
Outlook Therapeutics (OTLK)
ApprovedJul 24, 2026
Marketer take
An approved ophthalmic bevacizumab for wet AMD, entering a market where retina specialists already use off-label compounded bevacizumab, so the pitch centers on an FDA-approved, eye-specific formulation and price.
- Sponsor company
- Outlook Therapeutics (OTLK)
- Indication
- To treat patients with neovascular (wet) age-related macular degeneration
- Therapeutic area
- Ophthalmology
- Event
- FDA approval
- Date
- Jul 24, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?